🐻 HIMS Short Call Alert: Someone Just Collected $1.2M Betting Stock Stays Under $17!
📅 February 9, 2026 | 🔥 Unusual Activity Detected
🎯 The Quick Take
Someone just sold $1.2 MILLION worth of naked calls on HIMS, betting the stock stays pinned below $17 through March 20. This isn't a hedge - this is premium collection on a stock that just got hammered by a Novo Nordisk lawsuit and FDA crackdown. With HIMS trading at $17.69 and earnings on February 23, this trader is playing the "dead cat bounce" thesis - collect premium while the legal storm keeps a lid on any recovery.
🏢 Company Overview
Hims & Hers Health, Inc. (NYSE: HIMS) is a telehealth platform connecting patients with healthcare providers for treatments in erectile dysfunction, hair loss, skin care, mental health, and weight loss management.
| Metric | Value |
|---|---|
| Sector | Services - Offices & Clinics of Doctors of Medicine |
| Market Cap | $5.24B |
| Employees | 1,637 |
| Subscribers | 2.5 million |
| Headquarters | San Francisco, CA |
| Business Model | Direct-to-consumer (no insurance accepted) |
The company operates its own provider networks, electronic medical records systems, and cloud-based pharmacy fulfillment across all 50 U.S. states and select European markets including the UK.
💰 The Option Flow Breakdown
📊 What Just Happened
| Date | Time | Symbol | Direction | Type | Expiration | Strike | Volume | OI | Size | Spot | Premium | Option Symbol |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | 12:00:06 | HIMS | SELL | CALL | 2026-03-20 | $17 | 4,800 | 0 | 3,866 | $17.69 | $1.2M | HIMS20260320C17 |
🤓 What This Actually Means
Let me break this down for you:
📉 Short Call (STO - Sell to Open): This trader opened a brand new position by SELLING 4,800 call contracts at the $17 strike expiring March 20, 2026. They collected approximately $3.00 per share in premium ($1.2M total).
🎯 The Trade Logic:
- Maximum Profit: $1.2M (if HIMS closes at or below $17 at expiration)
- Breakeven: $20.00 ($17 strike + $3 premium)
- Maximum Loss: Unlimited (if HIMS rockets higher)
- Days to Expiration: 39 days (through the March Triple Witch)
💡 Translation: This trader believes HIMS has more downside ahead. With the stock at $17.69, they're betting it drops 4% or more - or at minimum stays rangebound - while they pocket that fat $1.2M premium. The fact they chose a strike below the current price (ITM call) shows aggressive conviction on the bearish thesis.
📈 Technical Setup / Chart Check-Up
YTD Performance
HIMS has been absolutely crushed in 2026. The stock has plunged approximately 50% from its 52-week high of $72.98 to current levels around $17-19. According to StockInvest analysis, the stock has declined in 8 of the last 10 trading days with an RSI of 23 indicating severely oversold conditions.
The chart tells a story of capitulation - a high-flying telehealth darling that ran headfirst into a regulatory buzzsaw.
🔵 Gamma-Based Support & Resistance Analysis
Based on current options positioning, here are the key gamma levels driving price action:
🛡️ Support Levels (Where Puts Create a Floor):
| Strike | Distance from Price | Net Gamma | Strength |
|---|---|---|---|
| $18.00 | -3.9% | -0.199 | ⭐⭐⭐ Strongest Support |
| $17.00 | -9.2% | -0.143 | ⭐⭐ Moderate Support |
| $16.00 | -14.6% | -0.032 | ⭐ Light Support |
| $15.00 | -19.9% | -0.133 | ⭐⭐ Moderate Support |
🚧 Resistance Levels (Where Calls Create a Ceiling):
| Strike | Distance from Price | Net Gamma | Strength |
|---|---|---|---|
| $19.00 | +1.4% | -0.081 | ⭐⭐ Immediate Resistance |
| $20.00 | +6.8% | -2.817 | ⭐⭐⭐⭐⭐ MAJOR Wall |
| $21.00 | +12.1% | -1.233 | ⭐⭐⭐⭐ Strong Resistance |
| $22.00 | +17.5% | -0.621 | ⭐⭐⭐ Moderate Resistance |
📊 Net GEX Bias: BEARISH - Total put gamma (19.74) exceeds call gamma (16.17), suggesting dealers will sell into rallies and buy dips, keeping price contained.
📉 Implied Move Analysis
The options market is pricing in significant volatility ahead:
| Timeframe | Expiry Date | Implied Move | Range |
|---|---|---|---|
| Weekly | 2026-02-13 | ±9.23% | $17.09 - $20.56 |
| Monthly OPEX | 2026-02-20 | ±12.94% | $16.39 - $21.26 |
| Triple Witch | 2026-03-20 | ±25.83% | $13.96 - $23.69 |
🎢 Translation: The market expects HIMS could swing nearly 26% in either direction by March expiration. That's earnings + legal uncertainty + regulatory overhang all baked into premium.
🎪 Catalysts
📅 Upcoming Catalysts
| Date | Event | Impact |
|---|---|---|
| Feb 23, 2026 | Q4 2025 Earnings | 🔥 CRITICAL - 2026 guidance, legal contingencies |
| Q1-Q2 2026 | Novo Nordisk Lawsuit Proceedings | ⚠️ HIGH - Potential "hundreds of millions" in damages |
| Q1-Q2 2026 | DOJ Investigation Outcome | ⚠️ HIGH - FDA referral could result in criminal penalties |
| May 2026 | Q1 2026 Earnings | 📊 First full quarter post-GLP-1 pivot |
📜 Recent Catalysts (Already Happened)
| Date | Event | Impact |
|---|---|---|
| Feb 9, 2026 | Novo Nordisk Patent Lawsuit Filed | 💔 MAJOR NEGATIVE - Seeking permanent injunction + treble damages |
| Feb 7, 2026 | Compounded Semaglutide Pill Pulled | 💔 Halted $49/month offering within 24 hours |
| Feb 6, 2026 | FDA Regulatory Crackdown | 💔 DOJ referral, 100+ warning letters industry-wide |
| Nov 3, 2025 | Q3 2025 Earnings | 📉 EPS miss ($0.06 vs $0.10 expected) |
| Nov 17, 2025 | $250M Share Buyback Authorized | 📈 Downside protection |
🎲 Price Targets & Probabilities
Based on gamma levels, implied move ranges, and the current catalyst environment:
🐻 Bear Case: $15.00 - $16.00 (35% probability)
Why it could happen:
- Novo Nordisk lawsuit creates prolonged legal overhang
- Q4 earnings disappoint or 2026 guidance slashed
- Weight loss segment revenue collapses without GLP-1 access
- Strong put gamma support at $15-16 suggests this is where the bleeding stops
Key Level: $15 represents a 20% decline from current price - well within the March implied move of ±26%
⚖️ Base Case: $17.00 - $19.00 (45% probability)
Why it's likely:
- Stock pins between $18 support and $19 resistance (gamma walls)
- Oversold bounce meets persistent selling pressure
- Legal uncertainty keeps buyers on the sideline
- Short call trader's $17 strike acts as a magnet
Key Level: $18 is the strongest gamma support - expect the stock to oscillate around this zone
🚀 Bull Case: $21.00 - $23.00 (20% probability)
Why it could happen:
- Q4 earnings beat with strong 2026 guidance
- Settlement talks with Novo Nordisk leak favorably
- Short squeeze potential (30-39% of float shorted per MarketBeat)
- Massive $20 gamma wall could flip from resistance to support if breached
Key Level: March implied move upper range of $23.69 aligns with analyst targets
💡 Trading Ideas
🛡️ Conservative: Cash-Secured Put at Support
The "Sleep Well at Night" Play:
- Trade: Sell the March 20 $15 Put
- Premium: ~$1.00-1.50 per share ($100-150 per contract)
- Max Profit: Premium collected if HIMS stays above $15
- Risk: Assigned at $15 with cost basis of ~$13.50-14.00
- Why This Works: You're getting paid to buy a beaten-down stock at an even lower price. The $15 strike is at strong gamma support and represents a 52-week low area. If assigned, you own HIMS at levels not seen since 2024.
- Capital Required: $1,500 per contract (cash-secured)
⚖️ Balanced: Bear Put Spread Through Earnings
The "Controlled Downside" Play:
- Trade: Buy the Feb 21 $18 Put / Sell the Feb 21 $16 Put
- Cost: ~$0.80 per share ($80 per spread)
- Max Profit: $1.20 per share ($120 per spread) if HIMS below $16 at Feb expiration
- Max Loss: $0.80 per share (premium paid)
- Risk/Reward: 1.5:1
- Why This Works: Earnings on Feb 23 could be ugly. This captures downside through monthly OPEX without holding through the report. The $16 short strike is at gamma support, limiting how far you need the stock to fall.
🚀 Aggressive: Follow the Whale - Short March Calls
The "Premium Collector" Play:
- Trade: Sell the March 20 $20 Covered Call (if you own shares) OR naked $22 Calls (advanced traders only)
- Premium: ~$1.50-2.00 per share for $20 strike
- Max Profit: Premium collected if HIMS stays below strike
- Risk: Unlimited for naked calls / capped upside for covered calls
- Why This Works: The $20 strike has a MASSIVE gamma wall - 10x more gamma than any other level. This is where market makers are heavily positioned, and it will act as a powerful ceiling. The short call whale chose this expiration for a reason.
- Capital Required: 100 shares for covered call, margin for naked
⚠️ Risk Factors
🚨 Legal & Regulatory Risks [CRITICAL]
- Novo Nordisk Lawsuit: Filed February 9, 2026 seeking permanent injunction and treble damages for patent infringement on US Patent 8,129,343. Potential exposure in the "hundreds of millions."
- DOJ Investigation: FDA referred HIMS to DOJ for potential legal action. Criminal penalties theoretically possible.
- Patent Wall: Semaglutide patent valid until 2032 - no compounding workaround available.
- FDA Enforcement: 100+ warning letters sent industry-wide with continued crackdown expected.
📉 Business Model Risks [HIGH]
- GLP-1 Revenue Dependency: Weight loss segment targeted $725M in 2025 - now requires complete pivot.
- Growth Deceleration: 2026 growth projected at 17% vs. 111% in Q1 2025 per Morgan Stanley.
- Margin Compression: Q4 EBITDA margin guidance ~10% vs. 13% full-year.
🎢 Short Squeeze Risk [ELEVATED]
- Short Interest: 72.25M shares (30-39% of float) shorted
- Any positive catalyst could trigger violent short covering
👤 Insider Activity [CAUTIONARY]
- Insiders sold 131,974 shares worth $4.76M in past 90 days
- CEO has made 46 sales vs. 2 buys over 5 years
🎯 The Bottom Line
Real talk: This $1.2M short call is a bet that HIMS stays underwater through March. The trader collected premium on a stock facing existential legal and regulatory risk - and they're probably right to do so.
📋 Action Plan:
If you're bullish on HIMS:
- Wait for earnings on February 23 before establishing new positions
- Consider selling cash-secured puts at the $15 support level
- Watch for settlement news with Novo Nordisk as a potential catalyst
If you're bearish or neutral:
- The short call strategy makes sense - collect premium while legal overhang persists
- Bear put spreads through earnings offer defined risk
- Avoid being short shares outright given 30%+ short interest (squeeze risk)
If you're already holding HIMS:
- Sell covered calls at the $20 gamma wall to generate income
- Consider taking partial profits on any bounce to $19
- Set stop loss below $15 gamma support
📅 Mark Your Calendar:
February 23, 2026 (14 days away): Q4 2025 earnings after market close. This is the moment of truth. Management's 2026 guidance and legal contingency disclosures will determine whether this stock stabilizes or breaks to new lows.